NextCure Phase 1 SIM0505 data: 55% ORR in gynecologic cancers; cash into Q1 2027

NextCure, Inc.

ORR of 55% (11/20) in gynecologic cancers at 4.8-8.0 mg/kg with ≥12 wks follow-up; 52.9% in ovarian, 66.7% in USC.
TEAEs leading to dose discontinuation in 3 patients (Gr2 ILD, Gr3 fungal pneumonia, Gr4 thrombocytopenia); no primary prophylaxis for hematologic toxicities used.
Patients heavily pretreated: median 5 prior systemic regimens (range 1-12); 78% ovarian cancer.
Cash, cash equivalents and marketable securities expected to fund operations into Q1 2027.
Virtual KOL event scheduled for June 2, 2026 at 8 AM ET.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.